B+
Bull case
25%
Probability
Target price
$315.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
CRL
Charles River Laboratories InternationalBNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
55%
Probability
Target price
$282.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$220.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-08
Recent news sentiment (30D)
+0.7
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+63.4
Score
AI commentary
The post-earnings tone is positive because Q2 results exceeded the packet’s pre-release framing, guidance increased, and DSA bookings improved. CRL closed at the RankAlpha anchor of $265.51 on August 6 and was quoted at $267.49 on August 7, a modest approximately 0.7% follow-through rather than an outsized repricing. Market reaction was therefore constructive but restrained, while the available analyst revision signal remained mixed. Social sentiment, options skew, short interest, and Glassdoor data are unavailable; this supports cautious monitoring rather than a high-conviction rerating call.
RankAlpha Sentiment Codex - 2026-08-08
Open post-earnings memoEvidence flagged
later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence
Impact
tentative
Confidence
-
AI events
2026-08-05eventQ2 results and FY2026 guidance raiseMedium impact
Q2 revenue was $1.00 billion, non-GAAP EPS was $3.02, organic revenue growth reached 0.1%, and management raised organic revenue guidance by 150 basis points and non-GAAP EPS guidance by $0.25 at the midpoint, citing improving DSA demand and better Manufacturing performance [#SEC-8K-2026-08-05].
2026-09-30catalystDSA booking and margin follow-throughMedium impact
The highest DSA net book-to-bill in nearly four years and broad-based demand improvement provide near-term support, but investors need evidence that bookings convert into revenue and margins after the guidance raise [#SEC-8K-2026-08-05].
2026-09-30catalystRMS weakness and cost execution riskMedium impact
RMS organic revenue declined 1.4% in Q2, while non-GAAP operating margin fell year over year because of higher DSA study-related direct costs and corporate costs. A renewed demand or margin setback could pressure the raised outlook [#SEC-8K-2026-08-05].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-08 • Updated nightlySource: Internal modelMethodology